ARXX Therapeutics ApS — Credit Rating and Financial Key Figures

ARXX Therapeutics ApS (CVR number: 40868151) is a company from HERLEV. The company reported a net sales of 2.6 mDKK in 2024, demonstrating a decline of -6.5 % compared to the previous year. The operating profit percentage was at 5.8 % (EBIT: 0.2 mDKK), while net earnings were 116.7 kDKK. The profitability of the company measured by Return on Assets (ROA) was 12.7 %, which can be considered good and Return on Equity (ROE) was 12.6 %, which can be considered good. The equity ratio, a key indicator for solidity, stood at 72.7 %, a level that can be considered to be good. This shows that a large part of the company's assets are funded by shareholders' equity, reducing financial risk. ARXX Therapeutics ApS's liquidity measured by quick ratio was 3.8 which is at a very high level. Thus, the company demonstrates exceptional financial stability, possessing a significant surplus of liquid assets over its short-term liabilities.